An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in United Arab Emirates. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, and was the 10th registered.
286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Italy
Ages 18–100
By country, each count listing its studies:
Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 175 across 73 observational studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.
This is a 24-week longitudinal single-arm prospective study based on data collected from EMRs along with patient-reported outcomes questionnaires (TSQM and DLQI) to evaluate patient-reported satisfaction and early quality of life experiences among HS patients who are newly initiated on Secukinumab. We will be using questionnaires at baseline and at week 24 to report on pre-defined outcomes in a representative HS population across the United Arab Emirates. The data will be collected using an electronic Case Report Form (eCRF) from both data sources (Electronic Medical Report and Questionnaires).
Patients with Hidradenitis Suppurativa who are newly initiated on Secukinumab, across the United Arab Emirates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are newly initiated on treatment with Secukinumab
Other: Secukinumab
This is an observational study. There is no treatment allocation.
The absolute scores of each of the 4 domains of the Treatment Satisfaction Questionnaire for Medication (TSQM) questionnaire
TSQM scoring is calculated by domain, and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher patient satisfaction. 4 Domains: Effectiveness Side Effects Convenience Global Satisfaction
Time frame: At Week 24
Change from baseline of the Dermatology Life Quality Index (DLQI) Questionnaire
DLQI is a questionnaire designed to measure the impact of skin conditions on a patient's health-related quality of life. It contains 10 simple, self-administered questions. Focuses on the past week's experiences related to the skin condition. Each question uses a 4-point Likert scale: "Not at all," "A little," "A lot," "Very much."
Time frame: Baseline, Week 24
Change from baseline in the Numerical Rating Scale (NRS)
The NRS is commonly used for measuring pain intensity and is well validated. It is scored from 0-10 (0 meaning no pain and 10 meaning the worst pain imaginable).
Time frame: Baseline, Week 24
Age (years)
Characteristics of Hidradenitis Suppurativa (HS) patients started on Secukinumab
Time frame: Baseline
Gender (male/female)
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Ethnicity
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Weight (kilogram)
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Height (meters)
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Socio-economic status
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Smoking status
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Duration of the disease (time since diagnosis)
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Previous HS-related treatment
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Time since diagnosis to start of the first treatment, and from time since diagnosis to start of Secukinumab
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Hurley Stage
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Number of inflammatory nodules, number of abscesses, and fistulas
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Previous HS-related surgeries
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Previous use of biologic treatment
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Previous and current use of antibiotics treatment
Characteristics of HS patients started on Secukinumab
Time frame: Baseline
Ran from Apr 2025 to primary completion in Jul 2026, 14 months.
Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2025 → Apr 2025, primary completion Oct 2026 → Jul 2026 and completion Oct 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.